Shares in Intercell AG rose by more than 8.5 percent Monday on news that the company's lead product, a vaccine against Japanese Encephalitis virus (JEV), received a positive opinion from the Committee on Human Medicinal Products, of the European Medicines Agency. (BioWorld International)